BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lantern Pharma Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Lantern Pharma Inc.'s drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05456256-2598@assetmemo.bio
DTSTAMP:20261121T005415Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dimesna: Phase 2 readout est. (NCT05456256)
DESCRIPTION:Dimesna\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Study
  of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced 
 Lung Adenocarcinoma\nEstimated primary completion: December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/dimesna#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05456256
URL:https://assetmemo.bio/drug/dimesna#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
